Loading...
•
Dec 31, 2020
Essa Pharma Q1 2021 Earnings Report
ESSA Pharma reported financial results for the fiscal first quarter ended December 31, 2020.
Key Takeaways
ESSA Pharma reported having cash reserves and short-term investments of $74,500,856 as of December 31, 2020, reflecting the gross proceeds of the July 2020 financing of $48.9 million, less operating expenses in the intervening period.
Raised $48.9 million in an over-subscribed public offering.
FDA granted Fast Track Designation to EPI-7386.
Initiated a Phase 1 trial with EPI-7386 for patients with metastatic castration-resistant prostate cancer.
Announced a clinical collaboration with Janssen Research & Development, LLC to evaluate EPI-7386 in combination clinical trials with abiraterone acetate/prednisone or apalutamide.